2021 is set to smash IPO records
Already been a banner year for equity raises via the IPO process in the U.S. — 2021 is on track to beat last year’s record
Aris Water sets IPO terms, to raise up to $318 million
Aris Water Solutions Inc. has set terms for its initial public offering, in which the profitable Texas-based water handling and recycling company is looking to raise up to $317.7 million. The company said it is offering 17.65 million Class A shares in the IPO, which is expected to price between $16 and $18 a share. With a total of 19.42 million Class A shares and 34.08 million Class B shares expected to be outstanding after the IPO, the pricing could value the company at up to $963.0 million. Th
Computing firm OVHcloud IPO set to go ahead at low end of price range
French cloud computing services provider OVHcloud’s IPO is set to move ahead at a price of 18.5 euros per share, at the low end of the range, one of the banks in charge of the operation said on Wednesday, valuing the firm at about 3.5 billion euros. One of the bookrunners said the IPO – which will likely be one of France’s biggest initial public offerings of the year – is already oversubscribed, although the books will not close until Thursday midday. On Oct. 5, OVHcloud – the second-biggest European-based cloud services provider after Deutsche Telekom’s T-Systems according to Synergy Research – had set a price range of 18.5 to 20 euros per share, which would lead to a market value of 3.50 to 3.74 billion euros.
TSMC announces chip plant in Japan, flags ‘tight’ capacity throughout 2022
TAIPEI (Reuters) -Taiwan chip giant TSMC announced on Thursday plans to build a new factory in Japan to meet long-term appetite for chips and said, near-term, tight supplies will likely continue into 2022 amid booming demand during the COVID-19 pandemic. TSMC, the world’s largest contract chipmaker and a key supplier to Apple Inc, said it would set up a chip plant in Japan that will use older chipmaking technology, a segment currently under a severe supply shortage due to robust demand from automakers and tech companies. The company and Taiwan in general have become central in efforts to resolve a pandemic-induced global chip shortage, which has forced automakers to cut production and hurt manufacturers of smartphones, laptops and consumer appliances.
5 Growth Stocks Climbing Up My Prospective Buy List
I don’t buy a lot of stocks. But with so many amazing businesses trading on the public markets, there are a lot that I want to buy. Many factors need to come together for me to press the buy button: the right allocation of paying myself first, an emergency fund, and funds available for investing.
Why Novavax Stock Is Absurdly Cheap Right Now
Novavax (NASDAQ: NVAX) has taken investors on a wild roller-coaster ride so far this year. After all of these dizzying gyrations, Novavax appears to be the biggest bargain among the top vaccine stocks. Here’s why Novavax stock is absurdly cheap right now.
Why BioXcel Therapeutics Stock Is Sinking Today
What happened Shares of BioXcel Therapeutics (NASDAQ: BTAI) were sinking 15.2% as of 11:25 a.m. EDT on Thursday. The decline came after the company’s regulatory filing to the Securities and Exchange Commission revealed that chief commercial officer William P.
11 Best Robinhood Stocks To Buy According To Hedge Funds
In this article, we discuss the 11 best Robinhood stocks to buy according to hedge funds. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Robinhood Stocks To Buy According To Hedge Funds. Equity trading applications have become more famous as the rapid digitization of the world […]
My Best Stocks to Buy Now and Hold Forever
If you want to build life-changing wealth, the stock market can be a great place to realize that dream. Since 1957, the S&P 500 has produced an annualized return of roughly 10.4% (including dividends).
Is It Too Late to Buy ChemoCentryx Stock?
The U.S. Food and Drug Administration (FDA) granted approval for the company’s autoimmune drug, avacopan, which instantly led to shares of ChemoCentryx more than doubling in value. For investors who didn’t want to take on the risk heading into the FDA decision, the obvious question now is whether it’s too late to invest in the healthcare stock. After amassing such impressive returns over a short time frame, can investors who buy the stock today still expect to earn a good return on their investment?
3 Growth Stocks That Could Double in 3 Years
Finding undervalued stocks in today’s market is getting more difficult, but there are plenty of strong companies that the market is still underestimating. Here’s why three Motley Fool contributors believe Academy Sports & Outdoors (NASDAQ: ASO), Dutch Bros (NYSE: BROS), and Roblox (NYSE: RBLX), can double in value in the next three years. John Ballard (Academy Sports & Outdoors): Academy Sports has tripled in value since its initial public offering in 2020.